Insider Selling: Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Sells $36,725.00 in Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Robin Swartz sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the transaction, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Voyager Therapeutics Trading Down 2.9 %

Shares of NASDAQ:VYGR opened at $5.74 on Friday. Voyager Therapeutics, Inc. has a twelve month low of $5.19 and a twelve month high of $11.72. The company has a market cap of $313.55 million, a PE ratio of 8.08 and a beta of 0.90. The company’s 50 day moving average is $6.31 and its 200 day moving average is $6.99.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. During the same period in the prior year, the firm earned ($0.59) EPS. Equities research analysts predict that Voyager Therapeutics, Inc. will post -0.89 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. StockNews.com cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Canaccord Genuity Group restated a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a research note on Thursday, November 14th. Leerink Partners assumed coverage on shares of Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective for the company. Finally, Wedbush started coverage on shares of Voyager Therapeutics in a research report on Friday, November 29th. They set an “outperform” rating and a $11.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $17.00.

Institutional Investors Weigh In On Voyager Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Great Point Partners LLC acquired a new position in shares of Voyager Therapeutics in the 2nd quarter valued at about $12,668,000. Erste Asset Management GmbH purchased a new position in Voyager Therapeutics during the third quarter valued at approximately $6,192,000. Armistice Capital LLC lifted its holdings in Voyager Therapeutics by 11.3% in the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after acquiring an additional 528,000 shares during the period. American Century Companies Inc. boosted its position in Voyager Therapeutics by 32.4% in the 2nd quarter. American Century Companies Inc. now owns 1,019,332 shares of the company’s stock worth $8,063,000 after purchasing an additional 249,659 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Voyager Therapeutics by 17.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 294,420 shares of the company’s stock worth $2,329,000 after purchasing an additional 44,289 shares during the period. 48.03% of the stock is owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.